Bio Royalty Investment Firm Executive Announces $8 Million Stake Sale

According to a recent filing by bio-royalty investment firm Royalty Pharma plc (RPRX), the combined Class A holdings managed by Butterfield Fiduciary Administrators Trust Company Limited for the Giuliani family trust and by Achille G. Severgnini have declined to approximately 4.8%, slipping below the 5% reporting threshold. As a result, the investors submitted a final “exit” amendment to Schedule 13D, reflecting only the management of existing holdings and past sales, with no new plans or activist intentions.

On June 23, Executive Vice President and Head of Partnering Christopher Hite sold 150,000 Class A common shares in the open market through SCH Investment Partners LLC under a pre-established Rule 10b5-1 trading plan, generating approximately $8.12 million (around KRW 110 billion) in proceeds.

Following the sale, Hite’s indirect holdings through SCH Investment Partners LLC fell to 559,399 Class A shares. The filing also disclosed that he directly owns 70,000 shares and holds rights via a family investment vehicle to convert into roughly 2.1 million additional Class A shares in the future.

In its first-quarter 2026 results, Royalty Pharma reported double-digit growth in portfolio receipts and raised its full-year 2026 guidance. On June 10, the company paid a second-quarter dividend of $0.235 per share.

As of June 29, the stock reached an all-time high of $56.57 per share, pushing the market capitalization to about $32.5 billion (approximately KRW 45 trillion).

Founded in 1996, Royalty Pharma plc specializes in biopharmaceutical royalty financing—providing upfront capital to new-drug patent holders in exchange for a percentage of future sales. The company went public on NASDAQ in 2020.

This royalty-financing model, which raises funds without diluting equity, is widely used across the biotech and pharmaceutical industries. Royalty Pharma is recognized as one of the world’s largest holders of biopharmaceutical royalty portfolios.